Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
Telix today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4...
Read moreLatest News
Category: News
Scintimun® Commercialization Partnership with Curium Pharma
Telix today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99mTc-besilesomab, also known as TLX66-CDx), a diagnostic...
Read more
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
Telix today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology...
Read more
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
Telix and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) have been published in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI)...
Read more
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
Telix today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®, 89Zr- girentuximab) kidney cancer...
Read more
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
News,
Telix today announces that it has completed the installation of two new cyclotrons at Telix Manufacturing Solutions (TMS) in Brussels South, Belgium, facilitating the production of radioisotopes and patient doses...
Read more
First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients
Telix and Grand Pharma today announce that a first patient has been dosed in the Phase III ZIRCON-CP trial of TLX250-CDx positron emission tomography (PET) imaging of clear cell renal...
Read more
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
Telix today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine. Telix’s development program...
Read more
Attack on Stroma – Targeting Fibroblast Activation Protein (FAP) to destroy cancer’s defences
News,
Cancer is a complex disease. Its growth is influenced not only by the cancer cells themselves but by its surroundings, known as the tumour microenvironment (TME). Telix is exploring a...
Read more
Telix ADSs Commence Trading on Nasdaq
Telix announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol...
Read more